Paul Thielking, MD, chief scientific officer for Novamind, discusses the company's current clinical trials, how psychedelics are garnering interest from physicians, and issues that will have to be navigated for psychedelics treatments in...
Paul Thielking, MD, chief scientific officer for Novamind, discusses the company's current clinical trials, how psychedelics are garnering interest from physicians, and issues that will have to be navigated for psychedelics treatments in...
Paul Thielking, MD, chief...